Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-005828 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Cindy Franklin und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany cindy.frankli…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Köln Fortune Program of the University of Cologne.
Abstract (Originalsprache)
Background
Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy.
Methods
Patients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC–V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS).
Results
Of 1704 patients, 916 were BRAF wild-type (BRAF wt ) and 788 were BRAF V600 mutant (BRAF mut ). Median follow-up time after start of 1L-therapy was 40.4 months. BRAF wt patients received 1L-therapy with immune checkpoint inhibitors (ICI) against CTLA-4+PD-1 (n=281) or PD-1 (n=544). In BRAF mut patients, 1L-therapy was ICI in 415 patients (CTLA-4+PD-1, n=108; PD-1, n=264), and BRAF+MEK targeted therapy (TT) in 373 patients. After 24 months, 1L-therapy with BRAF+MEK resulted in a higher incidence of brain metastasis compared with PD-1±CTLA-4 (BRAF+MEK, 30.3%; CTLA-4+PD-1, 22.2%; PD-1, 14.0%). In multivariate analysis, BRAF mut patients developed brain metastases earlier on 1L-therapy with BRAF+MEK than with PD-1±CTLA-4 (CTLA-4+PD-1: HR 0.560, 95% CI 0.332 to 0.945, p=0.030; PD-1: HR 0.575, 95% CI 0.372 to 0.888, p=0.013). Type of 1L-therapy, tumor stage, and age were independent prognostic factors for BMFS in BRAF mut patients. In BRAF wt patients, tumor stage was independently associated with longer BMFS; ECOG Performance status (ECOG-PS), lactate dehydrogenase (LDH), and tumor stage with OS. CTLA-4+PD-1 did not result in better BMFS, PFS, or OS than PD-1 in BRAF wt patients. For BRAF mut patients, multivariate Cox regression revealed ECOG-PS, type of 1L-therapy, tumor stage, and LDH as independent prognostic factors for PFS and OS. 1L-therapy with CTLA-4+PD-1 led to longer OS than PD-1 (HR 1.97, 95% CI 1.122 to 3.455, p=0.018) or BRAF+MEK (HR 2.41, 95% CI 1.432 to 4.054, p=0.001), without PD-1 being superior to BRAF+MEK.
Conclusions
In BRAF mut patients 1L-therapy with PD-1±CTLA-4 ICI resulted in a delayed and less frequent development of brain metastasis compared with BRAF+MEK TT. 1L-therapy with CTLA-4+PD-1 showed superior OS compared with PD-1 and BRAF+MEK. In BRAF wt patients, no differences in brain metastasis and survival outcomes were detected for CTLA-4+PD-1 compared with PD-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany cindy.franklin@uk-koeln.de.
- Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Cologne, Germany.
- Department of Dermatology, Elbe-Kliniken Buxtehude, Buxtehude, Germany.
- Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden and, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases (NCT), Dresden, Germany.
- Department of Dermatology, Skin Cancer Center, Schleswig-Holstein University Hospital, Campus Kiel, Kiel, Germany.
- Skin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hanover, Germany.
ORCID-Profile: Cindy Franklin, Friedegund Meier, Michael Weichenthal, Patrick Terheyden, Rudolf Herbst, Andrea Forschner, Alexander Kreuter, Christoffer Gebhardt, Bastian Schilling, Thilo Gambichler, Lucie Heinzerling, Jessica C Hassel, Maike Trommer, Jan-Malte Placke, Jürgen Christian Becker, Selma Ugurel
Förderung
- Köln Fortune Program of the University of Cologne
Zitieren
APA
Franklin, C., Mohr, P., Bluhm, L., Meier, F., Garzarolli, M., Weichenthal, M., Kähler, K., Grimmelmann, I., Gutzmer, R., Utikal, J., Terheyden, P., Herbst, R., Haferkamp, S., Pfoehler, C., Forschner, A., Leiter, U., Ziller, F., Meiss, F., Ulrich, J., …, & Ugurel, S. (2023). Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-005828
Vancouver
Franklin C, Mohr P, Bluhm L, Meier F, Garzarolli M, Weichenthal M, et al. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-005828
BibTeX
@article{Franklin2023,
author = {Franklin, Cindy and Mohr, Peter and Bluhm, Leonie and Meier, Friedegund and Garzarolli, Marlene and Weichenthal, Michael and Kähler, Katharina and Grimmelmann, Imke and Gutzmer, Ralf and Utikal, Jochen and Terheyden, Patrick and Herbst, Rudolf and Haferkamp, Sebastian and Pfoehler, Claudia and Forschner, Andrea and Leiter, Ulrike and Ziller, Fabian and Meiss, Frank and Ulrich, Jens and Kreuter, Alexander and Gebhardt, Christoffer and Welzel, Julia and Schilling, Bastian and Kaatz, Martin and Scharfetter-Kochanek, Karin and Dippel, Edgar and Nashan, Dorothee and Sachse, Michael and Weishaupt, Carsten and Löffler, Harald and Gambichler, Thilo and Loquai, Carmen and Heinzerling, Lucie and Grabbe, Stephan and Debus, Dirk and Schley, Gaston and Hassel, Jessica C and Weyandt, Gerhard and Trommer, Maike and Lodde, Georg and Placke, Jan-Malte and Zimmer, Lisa and Livingstone, Elisabeth and Becker, Jürgen Christian and Horn, Susanne and Schadendorf, Dirk and Ugurel, Selma},
title = {Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-005828}
}
EUVIMED